Drug Profile
Cimaglermin alfa - Acorda Therapeutics
Alternative Names: CGF-2; GGF-2 - Acorda; Glial growth factor 2 - Acorda; Neuregulin 1 protein; Neuregulin 1β3; NRG1 protein; Recombinant human glial growth factor-2 (rhGGF 2) - Acorda Therapeutics; rhGGF2 - AcordaLatest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer Acorda Therapeutics
- Class Growth factors; Heart failure therapies; Nerve tissue proteins; Neuregulins
- Mechanism of Action Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Heart failure; Neurological disorders; Stroke
Most Recent Events
- 29 Dec 2022 Suspended - Phase-I for Heart failure in USA (IV)
- 29 Dec 2022 Suspended - Preclinical for Neurological disorders in USA (SC)
- 29 Dec 2022 Suspended - Preclinical for Stroke in USA (SC)